Muscarinic agonists for the treatment of cognition in schizophrenia

CNS Spectrums

Volumn 13, Issue 11, 2008, Pages 985-996

  Sellin, Angela K ^a   Shad, Mujeeb ^b   Tamminga, Carol ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3 HEXYLTHIO 2 PYRAZINYLOXY) 1 AZABICYCLO[2.2.1]HEPTANE; AF 150; ALVAMELINE; BETHANECHOL; CEVIMELINE; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; DONEPEZIL; FLUPHENAZINE; GALANTAMINE; HALOPERIDOL; MESORIDAZINE; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; NEOSTIGMINE; NEUROLEPTIC AGENT; NORCLOZAPINE; OLANZAPINE; PHYSOSTIGMINE; PILOCARPINE; PLACEBO; QUETIAPINE; RISPERIDONE; THIORIDAZINE; UNCLASSIFIED DRUG; XANOMELINE; ZIPRASIDONE; CHOLINE;

ATRIOVENTRICULAR BLOCK; BLOOD PRESSURE; BRADYCARDIA; BRAIN STEM; CAUDATE NUCLEUS; CHOLINERGIC ACTIVITY; CHOLINERGIC SYSTEM; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CORPUS STRIATUM; DENTATE GYRUS; DIAPHORESIS; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FIRST PASS EFFECT; FOREBRAIN; FRONTAL CORTEX; GASTROINTESTINAL PAIN; GASTROINTESTINAL TRACT; HEART INFARCTION; HEART VENTRICLE EXTRASYSTOLE; HIPPOCAMPUS; HUMAN; KERATINOCYTE; KNOCKOUT MOUSE; LEARNING; MEMORY; MEMORY CONSOLIDATION; MEMORY DISORDER; NAUSEA AND VOMITING; NEOCORTEX; NEUROPHARMACOLOGY; NONHUMAN; NUCLEUS ACCUMBENS; ORBITAL CORTEX; PREFRONTAL CORTEX; PRIORITY JOURNAL; PUTAMEN; REVIEW; SALIVATION; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SUBICULUM; SUBSTANTIA NIGRA; SYNCOPE; THALAMUS; UROGENITAL SYSTEM; VISUAL SYSTEM; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; NEUROPSYCHOLOGICAL TEST;

ANIMALS; ANTIPSYCHOTIC AGENTS; CHOLINE; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; HUMANS; MUSCARINIC AGONISTS; NEUROPSYCHOLOGICAL TESTS; SCHIZOPHRENIA;

EID: 60249093377     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900014048     Document Type: Review

References (89)

1. Hyman SE, Fenton WS. Medicine: what are the right targets for psychopharmacology? Science. 2003;299:350-351.
2. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321-330.
3. Mohs RC. Assessing cognitive function in schizophrenics and patients with Alzheimer's disease. Schizophr Res. 1995;17(1):115-121.
4. Saykin AJ, Gur RC, Gur RE, et al. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry. 1991;48(7):618-624.
5. Saykin AJ, Shtasel DL, Gur RE, et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry. 1994;51(2):124-131.
6. Weickert TW, Goldberg TE. First- and second-generation antipsychotic medication and cognitive processing in schizophrenia. Curr Psychiatry Rep. 2005;7(4):304-310.
7. Carter CS, Braver TS, Barch DM, et al. Anterior cingulate cortex, error detection, and the online monitoring of performance. Science. 1998;280(5364):747-749.
8. Carter CS, Perlstein W, Ganguli R, et al. Functional hypofrontality and working memory dysfunction in schizophrenia. Am J Psychiatry. 1998;155(9):1285-1287.
9. Friedman JI, Adler DN, Howanitz E, et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry. 2002;51:349-357.
10. Peuskens J, Demily C, Thibaut F. Treatment of cognitive dysfunction in schizophrenia. Clin Ther. 2005;27(suppl 1):S25-S37.
11. Keefe RS, Bilder RM, Davis SM, et al; CATIE Investigators; Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007;64(6):633-647.
12. Keefe RS, Eesley CE, Poe MP. Defining a cognitive function decrement in schizophrenia. Biol Psychiatry. 2005;15;57(6):688-691.
13. Keefe RS, Bilder RM, Harvey PD, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology. 2006;31(9):2033-2046.
14. Marder SR. The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia. Dialogues Clin Neurosci. 2006;8(1):109-113.
15. Kern RS, Nuechterlein KH, Green MF, et al. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry. 2008;165(2):214-220.
16. Nuechterlein KH, Barch, DM, Gold, JM, et al. Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004;72(1):29-39.
17. Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;65(2):203-213.
18. Buchanan RW, Summerfelt A, Tek C, Gold J. An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res. 2002;59:29-33.
19. Friedman JI. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology (Berl). 2004;174(1):45-53.
20. Eglen RM. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Auton Autacoid Pharmacol. 2006; 26(3):219-233.
21. Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E. Decreased muscarinic receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry. 2002;7:1083-1091.
22. Li Z, Huang M, Ichikawa J, Dai J, Meltzer HY. N-Desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors. Neuropsychopharmacology. 2005;30(11):1986-1995.
23. Anagnostaras SG, Murphy GG, Hamilton SE, et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci. 2003;6(1):51-58.
24. Wess J. Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Annu Rev Pharmacol Toxicol. 2004;44(1):423-450.
25. Bymaster FP, Felder CC, Tzavara E, et al. Muscarinic mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1125-1143.
26. Wess J, Eglen RM, Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov. 2007;6:721-733.
27. Pinkas-Kramarski R, Stein R, Lindenboim L, Sokolovsky M. Growth factor-like effects mediated by muscarinic receptors in PC12M1 cells. J Neurochem. 1992;59(6):2158-2166.
28. Lindenboim L, Pinkas-Kramarski R, Sokolovsky M, Stein R. Activation of muscarinic receptors inhibits apoptosis in PC12M1 cells. J Neurochem. 1995;64:2491-2499.
29. Van Der Zee EA, Luiten PGM. Muscarinic acetycholine receptors in the hippocampus, neocortex and amygdala: A review of immunocytochemical localization in relation to learning and memory. Prog Neurobiol. 1999;58:409-471.
30. Aura J, Sirvio J, Riekkinen Jr P. Methoctramine moderately improves memory but pirenzepine disrupts performance in delayed non-matching to position test. Eur J Pharmacol. 1997;333:129-134.
31. McDonald MP, Willard LB, Wenk GL, Crawley JN. Coadministration of galanin antagonist M40 with a muscarinic M1 agonist improves delayed nonmatching to position choice accuracy in rats with cholinergic lesions. J Neurosci. 1998;18:5078-5085.
32. Terry AV, Buccafusco JJ, Borsini F, Leusch, A. Memory-related task performance by aged rhesus monkeys administered the muscarinic M1-preferring agonist, talsaclidine. Psychopharmacology. 2002;162(3):292-300.
33. Fisher A, Brandeis R, Chapman S, Pittel Z, Michaelson DM. (). M1 muscarinic agonist treatment reverses cognitive and cholinergic impairments of apolipoprotein E-deficient mice. J Neurochem. 1998;70:1991-1997.
34. Ruske AC, White KG. Facilitation of memory performance by a novel muscarinic agonist in young and old rats. Pharmacol Biochem Behav. 1999;63(4):663-667.
35. Brandeis R, Sapir M, Hafif N, et al. AF150(S): A new functionally selective M1 agonist improves cognitive performance in rats. Pharmacol Biochem Behav. 1995;51(4):667-674.
36. Hyde TM, Crook JM. Cholinergic systems and schizophrenia: primary pathology or epiphenomena? J Chem Neuroanat. 2001;22:53-63.
37. Levey AI, Edmunds SM, Koliatsos V, Wiley RG, Heilman CJ. Expression of m1-m4 muscarinic acetycholine receptor proteins in rat hippocampus and regulation by cholinergic innervation. J Neurosci. 1995;15(5):4077-4092.
38. Bymaster FP, Felder C, Ahmed S, McKinzie D. Muscarinic receptors as a target for drugs treating schizophrenia. Curr Drug Targets CNS Neurol Disord. 2002;1(2): 163-181.
39. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry. 2000;48:381-388.
40. Eglen RM, Choppin A, Dillon MP, Hegde S. Muscarinic receptor ligands and their therapeutic potential. Curr Opin Chem Biol. 1999;3(4):426-432.
41. Friedman JI, Temporini H, Davis KL. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry. 1999;45:1-16.
42. Mancama D, Arranz MJ, Landau S Kerwin R. Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2003;119B:2-6.
43. Scarr E, Keriakous D, Crossland N, Dean B. No change in cortical muscarinic M2, M3 receptors or [35S]GTPgammaS binding in schizophrenia. Life Sci. 2006;78(11):1231-1237.
44. Yeomans JS. Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacogy. 1995;12(1):3-16.
45. Zavitsanou K, Katsifis A, Mattner F, Huang XF. Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacogy. 2004;29(3):619-625.
46. Raedler TJ, Knable MB, Jones DW, et al. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry. 2003;160(1):118-27.
47. Han M, Newell K, Zavitsanou K, Deng C, Huang XF. Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain. J Neurosci Res. 2008;86(2):457-64.
48. Sarter M, Bruno JP. Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. Brain Res Brain Res Rev. 1997;23(1-2):28-46.
49. Liao DL, Hong CH, Chen HM, et al. Association of muscarinic m1 receptor genetic polymorphisms with psychiatric symptoms and cognitive function in schizophrenic patients. Neuropsychobiology. 2003;48(2):72-76.
50. Zakzanis KK, Andrikopoulos J, Young DA, Campbell Z, Sethian T. Neuropsychological differentiation of late-onset schizophrenia and dementia of the Alzheimer's type. Appl Neuropsychol. 2003;10(2):105-114.
51. Barch DM, Carter CS, Braver TS, et al. Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia. Arch Gen Psychiatry. 2001;58:280-288.
52. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 2001;158(2):176-184.
53. Brown JH, Taylor P. Muscarinic receptor agonists and antagonists. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill Professional; 2001;10(7):155-174.
54. Minzenberg MJ, Poole JH, Benton C, Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry. 2004;161:116-124.
55. Davies MA, Compton-Toth BA, Hufeisen SJ, Meltzer HY, Roth BL. The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions? Psychopharmacology. 2005;178(4):451-460.
56. Abi-Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry. 2005;20(1):15-27.
57. Kanba S, Suzuki E, Nomura S, et al. Affinity of neuroleptics for D1 receptor of human brain striatum. J Psychiatry Neurosci. 1994;19(4):265-269.
58. Weiner DM, Meltzer HY, Veinbergs I, et al. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology. 2004;177(1-2):207-216.
59. Wagner AD, Davachi L. Cognitive neuroscience: forgetting of things past. Curr Biol. 2001;11(23):R964-R967.
60. Ellis JR, Ellis KA, Bartholomeusz CF, et al. Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans. Int J Neuropsychopharmacol. 2006;9(2):175-189.
61. Drimer T, Shahal B, Barak Y. Effects of discontinuation of long-term anticholinergic treatment in elderly schizophrenia patients. Int Clin Psychopharmacol. 2004;19:27-29.
62. Goldsmith SK, Joyce JN. Alterations in hippocampal mossy fiber pathway in schizophrenia and alzheimer's disease. Biol Psychiatry. 1995;37:122-126.
63. White KE, Cummings, JL. Schizophrenia and Alzheimer's disease: clinical and pathophysiologic analogies. Compr Psychiatry. 1996;37(3):188-195.
64. Stryjer R, Bar F, Strous RD, Baruch Y, Rabey JM. Donepezil management of schizophrenia with associated dementia. J Clin Psychopharmacol. 2002;22(2):226-229.
65. MacEwan GW, Ehmann TS, Khanbhai I, Wrixon C. Donepezil in schizophrenia - is it helpful? An experimental design case study. Acta Psychiatr Scand. 2001;104(6):469-472.
66. Allen TB, McEvoy JP. Galantamine for treatment-resistant schizophrenia. Am J Psychiatry. 2002;159;1244-1245.
67. Buchanan RW, Conley RR, Dickinson D, et al. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry. 2008;165(1):82-89.
68. Kohler CG, Martin EA, Kujawski E, Bilker W, Gur RE, Gur RC. No Effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia. Cognit Neuropsychiatry. 2007;12(5):412-421.
69. Stip E, Sepehery AA, Chouinard S. Add-on therapy with acetylcholinesterase inhibitors for memory dysfunction in schizophrenia: a systematic quantitative review, Part 2. Clin Neuropharmacol. 2007;30(4):218-229.
70. Nahas Z, George MS, Horner MD, et al. Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study. Neurocase. 2003;9(3):274-282.
71. Schubert MH, Young KA, Hicks PB. Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry. 2006;60(6):530-533.
72. Lee SW, Lee JG, Lee BJ, Kim YH. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Int Clin Psychopharmacol. 2007;22(2):63-68.
73. Raedler TJ, Knable MB, Jones DW, Urbina RA, Egan MF, Weinberger DR. Central muscarinic acetylcholine receptor availability in patients treated with clozapine. Neuropsychopharmacogy. 2003;28:1531-1537.
74. Kay GG, Abou-Donia MB, Messer WS, Murphy DG, Tsao JW, Ouslander JG. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2005;53(12):2195-2201.
75. Bartolomeo AC, Morris H, Buccafusco JJ, et al. The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist. J Pharmacol Exp Ther. 2000;292(2):584-596.
76. Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol. 1997;54(4):465-473.
77. Guitton C, Abbar M, Kinowski J-M, Chabrand P, Bressolle F. Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. J Clinical Psychopharmacology. 1998;18(6);470-476.
78. Sauerberg P, Jeppesen L, Olesen PH, et al. Muscarinic agonists with antipsychotic-like activity: structure-activity relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist activity. J Med Chem. 1998;41(22):4378-4384.
79. Shannon HE, Rasmussen K, Bymaster F, et al. Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr Res. 2000;42:249-259.
80. Sur C, Mallorga PJ, Wittmann M, et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci U S A. 2003;100(23):13674-13679.
81. Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics. Available at: http://clinicaltrials.gov/ct2/show/ NCT00628420?term=NCT00628420&rank=1. Accessed September 15, 2008.
82. Thal LJ, Forrest M, Loft H, Mengel H. Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Neurology. 2000;54(2):421.
83. Young CD, Meltzer HY, Deutch AY. Effects of desmethylclozapine on fos protein expression in the forebrain: in vivo biological activity of the clozapine metabolite. Neuropsychopharmacogy. 1998;19(1):99-103.
84. Mirza NR, Peters D, Sparks RG. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev. 2003;9(2):159-186.
85. Jakubík J, Michal P, Machová E, Doležal V. Importance and prospects for design of selective muscarinic agonists. Physiol Res. 2008 May 13 [Epub ahead of print].
86. Shekhar A, Potter WZ, Lightfoot J, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry. 2008;165(8):1033-1039
87. Burstein ES, Ma JN, Wong S, et al. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther. 2005;315(3):1278-1287.
88. Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S. of N-desmethylclozapine as a potential antipsychotic - preclinical studies. Neuropsychopharmacology. 2007;32(7):1540-1549.
89. Lameh J, Burstein ES, Taylor E, Weiner DM, Vanover KE, Bonhaus DW. Pharmacology of N-desmethylclozapine. Pharmacol Ther. 2007;115(2):223-231.